KETs 2026 EU Brokerage Event

4–5 Feb 2026 | Karlsruhe, Germany

Register
Register
Register

ProductUpdated on 30 December 2025

MID Modality (Vaccine Innovation)

CEO & Founder at M Bio Technology Inc.

TOKYO, Japan

About

• World's first synthetic glycolipid antigen-based vaccines

• Designed for global standardization and deployment

  • Clinical Lead Partners: European University Hospitals

  • Public Health & Epidemiological Partners: Institutions

  • Regulatory & Market Access Experts: Partners familiar with EU MDR and the AI Act to navigate the fast-track approval process for MID Prism and MID Modality in Europe.

  • Horizon Europe Consortium Coordinators: Established EU entities looking for a high-tech Japanese SME to join proposals under Cluster 4 (Digital/Industry) or Cluster 1 (Health).

Organisation

M Bio Technology Inc.

SME

Setagaya, Tokyo, Japan

Similar opportunities